Business Overview: Helius Medical Technologies, Inc. (NASDAQ: HSDT)

---

Executive Summary

Helius Medical Technologies, Inc. is a neurotechnology company focused on neurological wellness, developing non-implantable technologies that reduce symptoms of neurological disease or trauma. Its flagship and only commercial product is the PoNS® (Portable Neuromodulation Stimulator), a device that delivers mild electrical stimulation through the tongue, paired with a 14-week supervised physical therapy program.

Helius matters because PoNS occupies a genuinely distinct therapeutic category — non-implantable, non-pharmacological neuromodulation — in a neurostimulation market otherwise dominated by surgically implanted devices, giving it a real "first-mover advantage" in its specific niche, by the company's own characterization.

---

1. Core Business Model & How They Work

Helius sells the PoNS device (controller plus mouthpiece) and generates recurring revenue from mouthpiece replacement, tied to a structured, clinically supervised treatment program.

[ Physician Prescribes PoNS Therapy ] ➡️ [ In-Clinic Treatment (first 2 weeks) ] ➡️ [ At-Home Treatment with Weekly Clinic Visits (12 weeks) ] ➡️ [ Device/Mouthpiece Sale + Reimbursement Claim ]

Key operational drivers:

1. Indication-by-indication regulatory expansion — PoNS has staggered authorizations: U.S. (MS gait deficit, 2021), Canada (mmTBI 2019, MS 2020, stroke 2023), and Australia (Class IIa, 2021, no commercial sales yet).
2. Device-plus-therapy bundle — the product is inseparable from its 14-week supervised physical therapy protocol, meaning Helius is really selling a clinical program, not just hardware.
3. Manufacturing transition — completed a move from Key Tronic to Minnetronix (St. Paul, MN) in Q4 2024, a supply-chain change that carries execution risk but aims to improve production.
4. Reimbursement navigation — actively disputes CMS's 2024/2025 HCPCS payment rates for both the controller and mouthpiece, which it views as inadequate, and plans formal appeals.

---

2. Business Segments

Helius does not report formal segments; it operates a single PoNS product line across multiple geographic authorizations (U.S., Canada, and pending Australia).

---

3. Product Portfolio

---

4. Competitive Landscape

Helius describes the broader neurostimulation market as dominated by surgically implanted, invasive technologies, which it says are not directly competitive with PoNS's non-implantable approach. It names no specific direct competitor companies, instead noting that "several large, publicly traded neurostimulation companies have greater access to capital and established pipelines" that could eventually target the non-implantable segment Helius currently leads.

The only named comparator product is Ampyra (dalfampridine), cited only as the one approved MS drug with a gait-speed indication — offered as a limited point of reference rather than a direct competitor, since it is a pharmacological rather than device-based treatment.

---

5. Strategic Strengths & Risks

Strengths

• Genuinely differentiated mechanism — non-implantable tongue-based neuromodulation is a distinct category from the implanted devices that dominate broader neurostimulation, giving Helius real first-mover positioning in its niche.
• Multiple regulatory authorizations across the U.S., Canada, and (pending commercialization) Australia diversify the addressable market beyond a single jurisdiction.
• Breakthrough Designation for the stroke indication could accelerate FDA review timelines if pivotal data support it.
• IP protection via 15 utility patents and 21 design patents, plus two 2025 provisional filings for next-generation technology, shows continued innovation investment.

Risks

• Reimbursement disputes — Helius is actively contesting CMS's HCPCS payment rates for both the controller and mouthpiece as inadequate, and the outcome of its planned appeals is uncertain; inadequate reimbursement directly threatens commercial viability.
• Manufacturing transition risk — the Q4 2024 shift from Key Tronic to Minnetronix introduces near-term supply continuity and quality-control risk during the changeover.
• The mmTBI indication, Helius's originally intended largest market opportunity, was denied in the U.S. in 2019 and remains shelved pending non-dilutive funding — a major unresolved setback.
• EU/UK market access remains stalled since the 2019 CE application withdrawal, limiting Helius's addressable market versus where it could otherwise be.
• Large, well-capitalized neurostimulation companies could enter the non-implantable segment and erode Helius's first-mover advantage if PoNS demonstrates commercial traction.

---

6. Financial Overview

---

7. Summary Conclusion

Helius Medical Technologies has built a genuinely novel neurotechnology category with PoNS — a non-implantable alternative in a neurostimulation market otherwise dominated by surgical devices — and has staged regulatory wins across the U.S., Canada, and Australia for multiple neurological indications. Its biggest forward risk is less about direct product competition today and more about economics: the gap between PoNS's premium list price and the CMS reimbursement rates Helius is actively disputing could determine whether the product achieves durable commercial adoption, even as the company simultaneously manages a manufacturing transition and works to revive its stalled mmTBI and EU/UK opportunities.